Premium
Collection of peripheral blood stem cells from normal donors 60 years of age or older
Author(s) -
Anderlini Paolo,
Przepiorka Donna,
Lauppe Jo,
Seong David,
Giralt Sergio,
Champlin Richard,
Körbling Martin
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.302677.x
Subject(s) - peripheral blood stem cells , peripheral blood , stem cell , medicine , hematology , peripheral , immunology , biology , hematopoietic stem cell transplantation , transplantation , genetics
We report 14 normal peripheral blood stem cell (PBSC) donors ≥ 60 years of age who had cytokine mobilization followed by PBSC apheresis for allogeneic transplantation. Mobilization was achieved with filgrastim (6 μg/kg twice daily). Their median age was 63.5 years (range 60–77), and 43% had a positive medical history, mainly hypertension and/or cardiac problems. Their median pre‐apheresis leucocyte count (×10 9 /l) was 38.6 (range 29.6–63.4). The median apheresis yield (×10 6 CD34 + cells/litre blood processed, first apheresis) was 27.9 (range 1.6–54.8). The target cell dose (≥4& times; 10 6 CD34 + cells/kg recipient) was reached with one procedure in eight (57%) donors. Filgrastim‐related adverse events were acceptable and apheresis was well tolerated. When compared to younger donors (<60 years of age), a trend to a lower CD34 + apheresis yield and a requirement for more than one apheresis to achieve the collection target (≥4 ×10 6 CD34 + cells/kg) was evident. Although older (≥60 years) donors seem to mobilize less effectively, these data suggest that PBSC collection from them is feasible and has an acceptable short‐term safety profile.